PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2 exchanger in guinea pig airway smooth muscle. PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 (IC50s ranging from 1 to 2.6 μM). PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors.

PPADS tetrasodiuma is potent at other native and recombinant P2XRs. PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner[2]. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and was highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ～1–3 and ～30 μM for the hP2X4R[3].

PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation. It also not altering the proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis[4].

192575-19-2

C14H14N3Na4O12PS2

603.34

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years